Home NDC 53217-223 Lidocaine
Product NDC 53217-223
11-digit product format 532170223
Labeler code 53217
Product ID 53217-223_862bed88-3e87-4d0b-9775-96ea41eed03d
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name Lidocaine Hydrochloride
Dosage form JELLY
Route TOPICAL
Labeler Aidarex Pharmaceuticals LLC
Application ANDA040837
Marketing category ANDA
Marketing start 2015-06-15
Marketing end 0000-00-00
Substance LIDOCAINE HYDROCHLORIDE
Active strength 20 mg/mL
Pharmacologic classes Amide Local Anesthetic [EPC],Amides [CS],Antiarrhythmic [EPC],Local Anesthesia [PE]
NDC exclude flag No
Listing certified through 2019-12-31
Current FDA listing Historical FDA.report record Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 2 · 66 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Code Status Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product D Discontinued by firm d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded product product I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 53217-223-01 D Discontinued by firm d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 53217-223-30 I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product D Discontinued by firm f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 53217-223-01 D Discontinued by firm f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 53217-223-30 I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product D Discontinued by firm 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 53217-223-01 D Discontinued by firm 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 53217-223-30 I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product D Discontinued by firm a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 53217-223-01 D Discontinued by firm a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 53217-223-30 I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product D Discontinued by firm cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 53217-223-01 D Discontinued by firm cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 53217-223-30 I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product D Discontinued by firm cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 53217-223-01 D Discontinued by firm cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 53217-223-30 I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product D Discontinued by firm 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product I Inactivated by FDA 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 53217-223-01 D Discontinued by firm 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 53217-223-30 I Inactivated by FDA 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product D Discontinued by firm ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product I Inactivated by FDA ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 53217-223-01 D Discontinued by firm ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 53217-223-30 I Inactivated by FDA ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product D Discontinued by firm 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product I Inactivated by FDA 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 53217-223-01 D Discontinued by firm 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 53217-223-30 I Inactivated by FDA 0efc9e666f02…f202fb6c5f17…2024-11-09 02:27 UTC · source 2024-11-08 excluded product product D Discontinued by firm ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded product product I Inactivated by FDA ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded package package 53217-223-01 D Discontinued by firm ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded package package 53217-223-30 I Inactivated by FDA ad56d346431e…cc804d4bbf1e…2024-10-04 04:10 UTC · source 2024-10-03 excluded product product D Discontinued by firm 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded product product I Inactivated by FDA 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded package package 53217-223-01 D Discontinued by firm 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded package package 53217-223-30 I Inactivated by FDA 367a005e9d99…383a685ebd0f…2024-07-10 04:00 UTC · source 2024-07-09 excluded product product D Discontinued by firm 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded product product I Inactivated by FDA 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded package package 53217-223-01 D Discontinued by firm 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded package package 53217-223-30 I Inactivated by FDA 557ba5c1ecfa…9c80585c8c6e…2024-05-28 21:12 UTC · source 2024-05-28 excluded product product I Inactivated by FDA 8af77b9d5b6f…d9bbb34c5368…2024-05-28 21:12 UTC · source 2024-05-28 excluded package package 53217-223-30 I Inactivated by FDA 8af77b9d5b6f…d9bbb34c5368…2024-05-15 03:39 UTC · source 2024-05-14 excluded product product I Inactivated by FDA 834df4deac94…adcc014656a3…2024-05-15 03:39 UTC · source 2024-05-14 excluded package package 53217-223-30 I Inactivated by FDA 834df4deac94…adcc014656a3…2024-03-11 06:39 UTC · source 2024-03-08 excluded product product I Inactivated by FDA 1332a3947898…d4bfe170f9cd…2024-03-11 06:39 UTC · source 2024-03-08 excluded package package 53217-223-30 I Inactivated by FDA 1332a3947898…d4bfe170f9cd…2022-08-30 03:57 UTC · source 2022-08-29 excluded product product I Inactivated by FDA fb8cb913e6d1…eb8c232b6be0…2022-08-30 03:57 UTC · source 2022-08-29 excluded package package 53217-223-30 I Inactivated by FDA fb8cb913e6d1…eb8c232b6be0…2022-04-09 23:13 UTC · source 2022-04-08 excluded product product I Inactivated by FDA 86f5da6cb304…a595104c45d7…2022-04-09 23:13 UTC · source 2022-04-08 excluded package package 53217-223-30 I Inactivated by FDA 86f5da6cb304…a595104c45d7…2022-04-04 05:40 UTC · source 2022-04-01 excluded product product I Inactivated by FDA bd6a592717d7…303034d00443…2022-04-04 05:40 UTC · source 2022-04-01 excluded package package 53217-223-30 I Inactivated by FDA bd6a592717d7…303034d00443…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A040837-001 LIDOCAINE HYDROCHLORIDE LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 43 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 84e616aacf4f…2026-08-18 06:07:40 2026-07 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 87673890dc5c…2021-03-12 10:30 UTC 2021-03 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 3f01610625f2…2019-09-15 20:21 UTC 2019-09 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 b00525d2431f…2019-07-19 19:46 UTC 2019-07 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 053a50430f4f…2023-01-26 05:58 UTC 2023-01 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 A040837-001 LIDOCAINE HYDROCHLORIDE 2% JELLY / TOPICAL 2011-03-23 f41ea6bd6efb…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 53217-223-30 Lidocaine 1 in 1 CARTON JELLY 1 2 53217-223-30 Lidocaine 30 mL in 1 TUBE, WITH APPLICATOR JELLY 30 2
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 53217-223 LIDOCAINE (LIDOCAINE HYDROCHLORIDE) JELLY [AIDAREX PHARMACEUTICALS LLC] 2 Legacy NDC, 2 package rows 20161123_46247b76-1ceb-4591-9aad-f5fbb5d5b0b8.zip
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Status 53217-223-30 53217022330 1 in 1 CARTON Historical